Please assess the completion status of the following clinical trial:

Trial Title: A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥18 years of age~* Severe hemophilia A (past evidence of circulating FVIII activity of \< 1% normal)~* Treated or exposed to FVIII concentrates or cryoprecipitate for at least 150 exposure days~* ≥12 bleeding episodes if receiving on-demand therapy over the preceding 12 months~* Agree to use double barrier contraceptive until at least 3 consecutive semen samples are negative for AAV 2/6 after SB-525 infusion~Exclusion Criteria:~* Presence of neutralizing antibodies~* Current inhibitor, or history of FVIII inhibitor (except for transient low titer inhibitor detected in childhood)~* History of hypersensitivity response to FVIII~* History of Hepatitis B or HIV-1/2 infection~* History of Hepatitis C, unless viral assays in two samples, collected at least 6 months apart, are negative~* Evidence of any bleeding disorder in addition to hemophilia A~* Markers of hepatic inflammation or overt or occult cirrhosis~* History of chronic renal disease or creatinine ≥ 1.5 mg/dL~* Presence of liver mass on magnetic resonance imaging (MRI), or, positive alpha fetoprotein~* Presence of \> grade 2 liver fibrosis on elastography for subjects with history of treated Hepatitis C or suspicion of chronic liver disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequential dose escalation (Type: EXPERIMENTAL): SB-525 (PF-07055480) is administered as a single infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).